370 related articles for article (PubMed ID: 15209578)
21. Acetylcysteine and non-ionic isosmolar contrast-induced nephropathy--a randomized controlled study.
Ferrario F; Barone MT; Landoni G; Genderini A; Heidemperger M; Trezzi M; Piccaluga E; Danna P; Scorza D
Nephrol Dial Transplant; 2009 Oct; 24(10):3103-7. PubMed ID: 19549691
[TBL] [Abstract][Full Text] [Related]
22. Usefulness of atorvastatin (80 mg) in prevention of contrast-induced nephropathy in patients with chronic renal disease.
Toso A; Maioli M; Leoncini M; Gallopin M; Tedeschi D; Micheletti C; Manzone C; Amato M; Bellandi F
Am J Cardiol; 2010 Feb; 105(3):288-92. PubMed ID: 20102936
[TBL] [Abstract][Full Text] [Related]
23. N-acetylcysteine versus N-acetylcysteine + theophylline for the prevention of contrast nephropathy.
Baskurt M; Okcun B; Abaci O; Dogan GM; Kilickesmez K; Ozkan AA; Ersanli M; Gurmen T
Eur J Clin Invest; 2009 Sep; 39(9):793-9. PubMed ID: 19500141
[TBL] [Abstract][Full Text] [Related]
24. The reno-protective effect of hydration with sodium bicarbonate plus N-acetylcysteine in patients undergoing emergency percutaneous coronary intervention: the RENO Study.
Recio-Mayoral A; Chaparro M; Prado B; Cózar R; Méndez I; Banerjee D; Kaski JC; Cubero J; Cruz JM
J Am Coll Cardiol; 2007 Mar; 49(12):1283-8. PubMed ID: 17394959
[TBL] [Abstract][Full Text] [Related]
25. Comparison of combination therapy of high-dose oral N-acetylcysteine and intravenous sodium bicarbonate hydration with individual therapies in the reduction of Contrast-induced Nephropathy during Cardiac Catheterisation and Percutaneous Coronary Intervention (CONTRAST): A multi-centre, randomised, controlled trial.
Chong E; Poh KK; Lu Q; Zhang JJ; Tan N; Hou XM; Ong HY; Azan A; Chen SL; Chen JY; Ali RM; Fang WY; Lau TW; Tan HC
Int J Cardiol; 2015 Dec; 201():237-42. PubMed ID: 26301645
[TBL] [Abstract][Full Text] [Related]
26. Prophylaxis of contrast-induced nephropathy in patients undergoing coronary angiography.
MacNeill BD; Harding SA; Bazari H; Patton KK; Colon-Hernadez P; DeJoseph D; Jang IK
Catheter Cardiovasc Interv; 2003 Dec; 60(4):458-61. PubMed ID: 14624421
[TBL] [Abstract][Full Text] [Related]
27. Effectiveness of theophylline in preventing contrast-induced nephropathy after coronary angiographic procedures.
Bilasy ME; Oraby MA; Ismail HM; Maklady FA
J Interv Cardiol; 2012 Aug; 25(4):404-10. PubMed ID: 22612071
[TBL] [Abstract][Full Text] [Related]
28. Contrast nephropathy in high-risk patients undergoing coronary angiography and intervention.
Uddin MA; Rabbani MA; Jafary FH; Bhatti MA; Islam M
J Coll Physicians Surg Pak; 2005 Dec; 15(12):791-4. PubMed ID: 16398973
[TBL] [Abstract][Full Text] [Related]
29. Preventive strategies of renal insufficiency in patients with diabetes undergoing intervention or arteriography (the PREVENT Trial).
Lee SW; Kim WJ; Kim YH; Park SW; Park DW; Yun SC; Lee JY; Kang SJ; Lee CW; Lee JH; Choi SW; Seong IW; Suh J; Cho YH; Lee NH; Cheong SS; Yoo SY; Lee BK; Lee SG; Hyon MS; Shin WY; Lee SW; Jang JS; Park SJ
Am J Cardiol; 2011 May; 107(10):1447-52. PubMed ID: 21420063
[TBL] [Abstract][Full Text] [Related]
30. Comparison of usefulness of simvastatin 20 mg versus 80 mg in preventing contrast-induced nephropathy in patients with acute coronary syndrome undergoing percutaneous coronary intervention.
Xinwei J; Xianghua F; Jing Z; Xinshun G; Ling X; Weize F; Guozhen H; Yunfa J; Weili W; Shiqiang L
Am J Cardiol; 2009 Aug; 104(4):519-24. PubMed ID: 19660605
[TBL] [Abstract][Full Text] [Related]
31. Sodium bicarbonate plus N-acetylcysteine to prevent contrast-induced nephropathy in primary and rescue percutaneous coronary interventions: the BINARIO (BIcarbonato e N-Acetil-cisteina nell'infaRto mIocardico acutO) study.
Leone AM; De Caterina AR; Sciahbasi A; Aurelio A; Basile E; Porto I; Trani C; Burzotta F; Niccoli G; Mongiardo R; Mazzari MA; Buffon A; Panocchia N; Romagnoli E; Lioy E; Rebuzzi AG; Crea F
EuroIntervention; 2012 Nov; 8(7):839-47. PubMed ID: 23171803
[TBL] [Abstract][Full Text] [Related]
32. Effect of hydration with or without n-acetylcysteine on contrast induced nephropathy in patients undergoing coronary angiography and percutaneous coronary intervention.
Awal A; Ahsan SA; Siddique MA; Banerjee S; Hasan MI; Zaman SM; Arzu J; Subedi B
Mymensingh Med J; 2011 Apr; 20(2):264-9. PubMed ID: 21522098
[TBL] [Abstract][Full Text] [Related]
33. Ascorbic acid prevents contrast-mediated nephropathy in patients with renal dysfunction undergoing coronary angiography or intervention.
Spargias K; Alexopoulos E; Kyrzopoulos S; Iokovis P; Greenwood DC; Manginas A; Voudris V; Pavlides G; Buller CE; Kremastinos D; Cokkinos DV
Circulation; 2004 Nov; 110(18):2837-42. PubMed ID: 15492300
[TBL] [Abstract][Full Text] [Related]
34. Impact of gender on the incidence and outcome of contrast-induced nephropathy after percutaneous coronary intervention.
Iakovou I; Dangas G; Mehran R; Lansky AJ; Ashby DT; Fahy M; Mintz GS; Kent KM; Pichard AD; Satler LF; Stone GW; Leon MB
J Invasive Cardiol; 2003 Jan; 15(1):18-22. PubMed ID: 12499523
[TBL] [Abstract][Full Text] [Related]
35. Safety and efficacy of anisodamine on prevention of contrast induced nephropathy in patients with acute coronary syndrome.
Wang YB; Fu XH; Gu XS; Wang XC; Zhao YJ; Hao GZ; Jiang YF; Fan WZ; Wu WL; Li SQ; Xue L
Chin Med J (Engl); 2012 Mar; 125(6):1063-7. PubMed ID: 22613532
[TBL] [Abstract][Full Text] [Related]
36. Intrarenal application of N-acetylcysteine for the prevention of contrast medium-induced nephropathy in primary angioplasty.
Aslanger E; Uslu B; Akdeniz C; Polat N; Cizgici Y; Oflaz H
Coron Artery Dis; 2012 Jun; 23(4):265-70. PubMed ID: 22343798
[TBL] [Abstract][Full Text] [Related]
37. Contrast-induced nephropathy in patients undergoing primary angioplasty for acute myocardial infarction.
Marenzi G; Lauri G; Assanelli E; Campodonico J; De Metrio M; Marana I; Grazi M; Veglia F; Bartorelli AL
J Am Coll Cardiol; 2004 Nov; 44(9):1780-5. PubMed ID: 15519007
[TBL] [Abstract][Full Text] [Related]
38. N-acetylcysteine does not prevent contrast-induced nephropathy after cardiac catheterization in patients with diabetes mellitus and chronic kidney disease: a randomized clinical trial.
Amini M; Salarifar M; Amirbaigloo A; Masoudkabir F; Esfahani F
Trials; 2009 Jun; 10():45. PubMed ID: 19563648
[TBL] [Abstract][Full Text] [Related]
39. B-type natriuretic peptide for prevention of contrast-induced nephropathy in patients with heart failure undergoing primary percutaneous coronary intervention.
Zhang J; Fu X; Jia X; Fan X; Gu X; Li S; Wu W; Fan W; Su J; Hao G; Jiang Y; Xue L
Acta Radiol; 2010 Jul; 51(6):641-8. PubMed ID: 20438292
[TBL] [Abstract][Full Text] [Related]
40. Prevention of acute renal failure post-contrast imaging in cardiology: a randomized study.
Alessandri N; Lanzi L; Garante CM; Tersigni F; Sergiacomi R; Petrassi M; Di Matteo A; Tufano F
Eur Rev Med Pharmacol Sci; 2013 Feb; 17 Suppl 1():13-21. PubMed ID: 23436661
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
